Register for streaming realtime charts, analysis tools, and prices.
Halozyme (NASDAQ: HALO) has a potential breakthrough in new therapeutic combination represents how pancreatic cancer has evaded standard treatments for patients.
PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors, and has shown promising data recently. Additionally, company director Kathryn E. Falberg bought $681.6K of the company’s stock, at an average cost of $6.82 a share. This “buy” was not an option grant, but an actual open market buy, where she is actually risking her own money. Falberg has had major success before investing in a company where she was a sitting board member. On 08/31/2010 Falberg bought 50,000 shares of Jazz Pharma (NASDAQ: JAZZ) at an average price of $8.72 a share.
Jazz has three major drugs on the market – Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy, Erwinaze to treat acute lymphoblastic leukemia, and Prialt for the management of severe chronic pain. All of these have proven to be successful for the company. Lately, the buzz surrounding Jazz has been its rumored acquisition interest, causing a further rally in the stock to over $88 a share. The following video below explains Halozyme’s platform for treating Pancreatic Cancer. At StockMatusow, we believe Halo’s stock has the potential to increase in value 5 fold, over the next 3 years. Lately, the call activity has been very bullish for the stock.
Breakthrough Understanding in Pancreatic Cancer Therapy from Patient Power® on Vimeo.
